{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:05:53Z","timestamp":1792191953650,"version":"4.4.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:p>Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by a fusion gene, encoding for the chimeric protein BCR-ABL, with constitutive tyrosine kinase activity. The use of tyrosine kinase inhibitors (TKIs) has drastically improved survival, but there are significant concerns about cardiovascular toxicity. Cardiovascular risk can be lowered with appropriate baseline evaluation, accurate choice of TKI therapy, improvement of modifiable cardiovascular risk factors through lifestyle modifications, and prescription of drugs for primary or secondary prevention. Which examinations are necessary, and when do they have to be scheduled? How often should a TKI-treated patient undergo which cardiology test or exam? Is there an accurate way to estimate the risk that each TKI may determine a cardiovascular adverse event in a CML patient? In a few words, how can we optimize the cardiovascular risk management in CML patients before and during TKI treatment? The aim of this review is to describe cardiac and vascular toxicity of TKIs used for CML treatment according to the most recent literature and to identify unmet clinical needs in cardiovascular risk management and complications in these patients. Regarding the TKI-induced cardiovascular toxicity, the full mechanism is still unclear, but it is accepted that different factors may play different roles: endothelial damage and atherosclerosis, metabolic impairment, hypertensive effect, glomerular impairment, and mast-cell disruption. Preventive strategies are aimed at minimizing cardiovascular risk when CML is diagnosed. Cardio-oncology units in specialized hematology centers may afford a personalized and multidisciplinary approach to the patient, optimizing the balance between treatment of the neoplasm and management of cardiovascular risk.<\/jats:p>","DOI":"10.3389\/fphys.2021.675811","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T07:07:01Z","timestamp":1625468821000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review"],"prefix":"10.3389","volume":"12","author":[{"given":"Marco","family":"Santoro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatrice","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Accurso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Di Lisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Siragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/vhrm.s108874","article-title":"Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.","volume":"13","author":"Aghel","year":"2017","journal-title":"Vasc. Health Risk Manag."},{"key":"B2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/1078155210378913","article-title":"Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.","volume":"17","author":"Agostino","year":"2011","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.thromres.2016.07.019","article-title":"The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state.","volume":"145","author":"Alhawiti","year":"2016","journal-title":"Thromb. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"72311","DOI":"10.18632\/oncotarget.11100","article-title":"Genetic predisposition and induced pro-inflammatory\/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.","volume":"7","author":"Bocchia","year":"2016","journal-title":"Oncotarget"},{"key":"B5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00277-014-2231-9","article-title":"Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment.","volume":"94","author":"Breccia","year":"2015","journal-title":"Ann. Hematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bjh.13801","article-title":"Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.","volume":"172","author":"Br\u00fcmmendorf","year":"2016","journal-title":"Br. J. Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1161\/circulationaha.116.023164","article-title":"Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus.","volume":"134","author":"Capodanno","year":"2016","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ajh.24360","article-title":"Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.","volume":"91","author":"Cortes","year":"2016","journal-title":"Am. J. Hematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clml.2016.09.012","article-title":"Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: identification and Management.","volume":"17","author":"Cortes","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome\u2013positive leukemia: final 5-year results of the phase 2 PACE trial.","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/circulationaha.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study.","volume":"117","author":"D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.","volume":"141","author":"de Lavallade","year":"2008","journal-title":"Br. J. Haematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients.","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: a Systematic Review and Meta-analysis.","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/nejm200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1056\/nejmoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction.","volume":"367","author":"Emerging Risk Factors Collaboration, Kaptoge","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia.","volume":"341","author":"Faderl","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrd3252","article-title":"Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.","volume":"10","author":"Force","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"B19","doi-asserted-by":"publisher","first-page":"26077","DOI":"10.1074\/jbc.m705008200","article-title":"Role of c-Abl in directing metabolic versus mitogenic effects in insulin receptor signaling.","volume":"282","author":"Frasca","year":"2007","journal-title":"J. Biol. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/14740338.2019.1613371","article-title":"An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy.","volume":"18","author":"Galvano","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/ajh.23788","article-title":"Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am. J. Hematol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/s0083-6729(08)00604-3","article-title":"c-Abl and insulin receptor signalling.","volume":"80","author":"Genua","year":"2009","journal-title":"Vitam. Horm."},{"key":"B23","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMc051946","article-title":"Imatinib for the treatment of pulmonary arterial hypertension.","volume":"29","author":"Ghofrani","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1172\/jci86249","article-title":"Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.","volume":"126","author":"Guignabert","year":"2016","journal-title":"J. Clin. Invest."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1038\/leu.2017.245","article-title":"Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.","volume":"31","author":"Hadzijusufovic","year":"2017","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3389\/fphar.2020.01007","article-title":"The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: an In-Vitro Study.","volume":"11","author":"Haguet","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B28","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"crossref","first-page":"H1054","DOI":"10.1152\/ajpheart.1998.274.3.H1054","article-title":"VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells.","volume":"274","author":"Hood","year":"1998","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","article-title":"Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1097\/hjh.0b013e3283309b59","article-title":"Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects.","volume":"27","author":"Kappers","year":"2009","journal-title":"J. Hypertens."},{"key":"B33","doi-asserted-by":"crossref","first-page":"H586","DOI":"10.1152\/ajpheart.1993.265.2.H586","article-title":"Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries.","volume":"265","author":"Ku","year":"1993","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coph.2014.11.010","article-title":"Etiology of angiogenesis inhibition-related hypertension.","volume":"21","author":"Lankhorst","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"B35","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","article-title":"Vascular and Metabolic Implications of Novel Targeted Cancer Therapies.","volume":"66","author":"Li","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/s1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719826444","article-title":"Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia.","volume":"10","author":"Molica","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"B38","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib.","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/nejmra1100265","article-title":"Cardiovascular Toxic Effects of Targeted Cancer Therapies.","volume":"375","author":"Moslehi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/jco.2015.62.4718","article-title":"Tyrosine Kinase Inhibitor\u2013Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.","volume":"33","author":"Moslehi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/bcp.13508","article-title":"Dasatinib-induced pulmonary arterial hypertension.","volume":"84","author":"\u00d6zg\u00fcr Yurtta\u015f","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","article-title":"Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.","volume":"144","author":"Ross","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000504664","article-title":"Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors.","volume":"64","author":"Santoro","year":"2019","journal-title":"Chemotherapy"},{"key":"B44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.leukres.2017.05.008","article-title":"Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.","volume":"59","author":"Valent","year":"2017","journal-title":"Leuk. Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis.","volume":"23","author":"Vener","year":"2020","journal-title":"Blood Adv."},{"key":"B46","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/s0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2021.675811\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T07:07:07Z","timestamp":1625468827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2021.675811\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":46,"alternative-id":["10.3389\/fphys.2021.675811"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2021.675811","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"article-number":"675811"}}